Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO23--Castle will share new data on its DecisionDx®-SCC test at the American Society for Radiatio...
October 3, 2023
11:00 AM
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO23--Castle will share new data on its DecisionDx®-SCC test at the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting.